{"id":"malaria-challenge","safety":{"commonSideEffects":[{"effect":"Pain- solicited local (post-vaccination)","drugRate":"96.4%","placeboRate":"","totalAtRisk":28,"totalAffected":27,"trialsReporting":1},{"effect":"Headache","drugRate":"38.8%","placeboRate":"","totalAtRisk":67,"totalAffected":26,"trialsReporting":6},{"effect":"Injection site pain","drugRate":"76.7%","placeboRate":"","totalAtRisk":30,"totalAffected":23,"trialsReporting":2},{"effect":"Headache- solicited general (post-vaccination)","drugRate":"75.0%","placeboRate":"","totalAtRisk":28,"totalAffected":21,"trialsReporting":1},{"effect":"Fatigue","drugRate":"33.3%","placeboRate":"","totalAtRisk":51,"totalAffected":17,"trialsReporting":4},{"effect":"Fatigue (post-vaccination)","drugRate":"30.4%","placeboRate":"","totalAtRisk":56,"totalAffected":17,"trialsReporting":2},{"effect":"Redness (post-vaccination)","drugRate":"53.6%","placeboRate":"","totalAtRisk":28,"totalAffected":15,"trialsReporting":1},{"effect":"Chills (post-vaccination)","drugRate":"53.6%","placeboRate":"","totalAtRisk":28,"totalAffected":15,"trialsReporting":1},{"effect":"Injection site erythema","drugRate":"53.8%","placeboRate":"","totalAtRisk":26,"totalAffected":14,"trialsReporting":1},{"effect":"Malaria (post-challenge)","drugRate":"56.0%","placeboRate":"","totalAtRisk":25,"totalAffected":14,"trialsReporting":1},{"effect":"Swelling (post-vaccination)","drugRate":"46.4%","placeboRate":"","totalAtRisk":28,"totalAffected":13,"trialsReporting":1},{"effect":"Injection site swelling","drugRate":"34.6%","placeboRate":"","totalAtRisk":26,"totalAffected":9,"trialsReporting":1},{"effect":"Gastrointestinal disorder","drugRate":"34.6%","placeboRate":"","totalAtRisk":26,"totalAffected":9,"trialsReporting":1},{"effect":"Pyrexia","drugRate":"15.7%","placeboRate":"","totalAtRisk":51,"totalAffected":8,"trialsReporting":4},{"effect":"Upper respiratory tract infection (post-vaccination)","drugRate":"21.4%","placeboRate":"","totalAtRisk":28,"totalAffected":6,"trialsReporting":1},{"effect":"Temperature (post-vaccination)","drugRate":"21.4%","placeboRate":"","totalAtRisk":28,"totalAffected":6,"trialsReporting":1},{"effect":"Pain (post-vaccination)","drugRate":"17.9%","placeboRate":"","totalAtRisk":28,"totalAffected":5,"trialsReporting":1},{"effect":"Headache (post-challenge)","drugRate":"20.0%","placeboRate":"","totalAtRisk":25,"totalAffected":5,"trialsReporting":1},{"effect":"Gastrointestinal symptoms (post-vaccination)","drugRate":"17.9%","placeboRate":"","totalAtRisk":28,"totalAffected":5,"trialsReporting":1},{"effect":"Chills","drugRate":"8.5%","placeboRate":"","totalAtRisk":47,"totalAffected":4,"trialsReporting":3},{"effect":"Back pain (post-vaccination)","drugRate":"14.3%","placeboRate":"","totalAtRisk":28,"totalAffected":4,"trialsReporting":1},{"effect":"Dizziness","drugRate":"5.9%","placeboRate":"","totalAtRisk":51,"totalAffected":3,"trialsReporting":4},{"effect":"Upper respiratory tract infection","drugRate":"7.0%","placeboRate":"","totalAtRisk":43,"totalAffected":3,"trialsReporting":2},{"effect":"Back Pain","drugRate":"25.0%","placeboRate":"","totalAtRisk":12,"totalAffected":3,"trialsReporting":1},{"effect":"Sunburn","drugRate":"17.6%","placeboRate":"","totalAtRisk":17,"totalAffected":3,"trialsReporting":1},{"effect":"Headache (post-vaccination)","drugRate":"10.7%","placeboRate":"","totalAtRisk":28,"totalAffected":3,"trialsReporting":1},{"effect":"Dysmenorrhoea (post-vaccination)","drugRate":"10.7%","placeboRate":"","totalAtRisk":28,"totalAffected":3,"trialsReporting":1},{"effect":"Oropharyngeal pain(post-challenge)","drugRate":"12.0%","placeboRate":"","totalAtRisk":25,"totalAffected":3,"trialsReporting":1},{"effect":"Insomnia","drugRate":"4.8%","placeboRate":"","totalAtRisk":42,"totalAffected":2,"trialsReporting":3},{"effect":"Myalgia","drugRate":"3.6%","placeboRate":"","totalAtRisk":55,"totalAffected":2,"trialsReporting":5},{"effect":"Nausea","drugRate":"4.9%","placeboRate":"","totalAtRisk":41,"totalAffected":2,"trialsReporting":5},{"effect":"Pain","drugRate":"6.7%","placeboRate":"","totalAtRisk":30,"totalAffected":2,"trialsReporting":2},{"effect":"Neck pain","drugRate":"4.7%","placeboRate":"","totalAtRisk":43,"totalAffected":2,"trialsReporting":2},{"effect":"Viral upper respiratory tract infection","drugRate":"4.7%","placeboRate":"","totalAtRisk":43,"totalAffected":2,"trialsReporting":2},{"effect":"Erythema","drugRate":"4.7%","placeboRate":"","totalAtRisk":43,"totalAffected":2,"trialsReporting":2},{"effect":"Local Reaction","drugRate":"16.7%","placeboRate":"","totalAtRisk":12,"totalAffected":2,"trialsReporting":1},{"effect":"Malaise (post-vaccination)","drugRate":"7.1%","placeboRate":"","totalAtRisk":28,"totalAffected":2,"trialsReporting":1},{"effect":"Nasopharyngitis (post-vaccination)","drugRate":"7.1%","placeboRate":"","totalAtRisk":28,"totalAffected":2,"trialsReporting":1},{"effect":"Throat irritation","drugRate":"7.1%","placeboRate":"","totalAtRisk":28,"totalAffected":2,"trialsReporting":1},{"effect":"Pruritus (post-vaccination)","drugRate":"7.1%","placeboRate":"","totalAtRisk":28,"totalAffected":2,"trialsReporting":1},{"effect":"Abdominal pain","drugRate":"2.1%","placeboRate":"","totalAtRisk":47,"totalAffected":1,"trialsReporting":3},{"effect":"Arthralgia","drugRate":"2.0%","placeboRate":"","totalAtRisk":51,"totalAffected":1,"trialsReporting":4},{"effect":"Cough","drugRate":"2.4%","placeboRate":"","totalAtRisk":42,"totalAffected":1,"trialsReporting":3},{"effect":"Decreased appetite","drugRate":"2.1%","placeboRate":"","totalAtRisk":47,"totalAffected":1,"trialsReporting":3},{"effect":"Gastritis","drugRate":"25.0%","placeboRate":"","totalAtRisk":4,"totalAffected":1,"trialsReporting":1},{"effect":"Malaise","drugRate":"2.0%","placeboRate":"","totalAtRisk":51,"totalAffected":1,"trialsReporting":4},{"effect":"Neutropenia","drugRate":"4.0%","placeboRate":"","totalAtRisk":25,"totalAffected":1,"trialsReporting":3},{"effect":"Vomiting","drugRate":"12.5%","placeboRate":"","totalAtRisk":8,"totalAffected":1,"trialsReporting":2},{"effect":"Asthenia","drugRate":"3.8%","placeboRate":"","totalAtRisk":26,"totalAffected":1,"trialsReporting":1},{"effect":"Chest pain","drugRate":"3.8%","placeboRate":"","totalAtRisk":26,"totalAffected":1,"trialsReporting":1}]},"_chembl":{"chemblId":"CHEMBL1213553","moleculeType":"Small molecule","molecularWeight":"288.18"},"_dailymed":null,"_scrapedAt":"2026-03-28T04:16:23.777Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T10:12:10.881344+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT07257965","phase":"NA","title":"Clinical Study to Assess Minimum Mosquito Bites for P. Vivax Infection in Thai Adults","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2026-02-02","conditions":"Plasmodium Vivax Infection","enrollment":24},{"nctId":"NCT06735209","phase":"PHASE1","title":"First-in-Human PfSPZ-LARC2 Vaccination/CHMI","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-07-23","conditions":"Malaria","enrollment":22},{"nctId":"NCT02639299","phase":"","title":"Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-12-08","conditions":"Malaria","enrollment":1500},{"nctId":"NCT06862453","phase":"PHASE1","title":"Safety, Tolerability and Efficacy Against Controlled Human Malaria Infection of PfSPZ-LARC2 Vaccine in Malaria-naïve Adults","status":"NOT_YET_RECRUITING","sponsor":"Sanaria Inc.","startDate":"2026-03","conditions":"Malaria Falciparum","enrollment":58},{"nctId":"NCT06607003","phase":"PHASE1","title":"Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-11-26","conditions":"Malaria","enrollment":300},{"nctId":"NCT04478370","phase":"NA","title":"Characterizing Humoral Immune Response to Mosquito Bites","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2021-01-21","conditions":"Malaria, Dengue","enrollment":147},{"nctId":"NCT04083508","phase":"NA","title":"Vivax Malaria Human Infection Studies in Thailand","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2020-10-05","conditions":"Plasmodium Vivax Infection","enrollment":6},{"nctId":"NCT05071079","phase":"NA","title":"A Controlled Human Vivax Malaria Infection Study Through Inoculation of Infected Erythrocytes","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2022-05-23","conditions":"Plasmodium Vivax Infection","enrollment":48},{"nctId":"NCT05979207","phase":"PHASE1","title":"Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2023-08-01","conditions":"Infections, Vector Borne Diseases, Systemic Inflammatory Response Syndrome","enrollment":12},{"nctId":"NCT07124156","phase":"PHASE1","title":"A Challenge Study to Assess the Blood-stage Efficacy of Full-length SUM-101 Malaria Vaccine Candidate","status":"NOT_YET_RECRUITING","sponsor":"European Vaccine Initiative","startDate":"2026-03-20","conditions":"Malaria Fever","enrollment":24},{"nctId":"NCT03797989","phase":"EARLY_PHASE1","title":"VAC069: A Study of Blood-stage Controlled Human P. Vivax Infection","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-01-10","conditions":"Malaria, Vivax","enrollment":19},{"nctId":"NCT03168854","phase":"PHASE1","title":"Trial to Evaluate the Safety, Immunogenicity and Protective Efficacy of Three or Five Administrations of GAP3KO Sporozoites","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-07-26","conditions":"Plasmodium Falciparum Infection","enrollment":26},{"nctId":"NCT03947190","phase":"PHASE2","title":"A Study to Determine if New Types of Malaria Vaccines Are Safe, Effective and Lead to Immunity in Kenyan Adults","status":"TERMINATED","sponsor":"University of Oxford","startDate":"2022-08-31","conditions":"Malaria,Falciparum","enrollment":80},{"nctId":"NCT06294912","phase":"PHASE1","title":"A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-18","conditions":"Malaria","enrollment":16},{"nctId":"NCT03503058","phase":"PHASE2","title":"Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted Malaria","status":"COMPLETED","sponsor":"Sanaria Inc.","startDate":"2022-05-07","conditions":"Malaria","enrollment":345},{"nctId":"NCT05441410","phase":"PHASE1, PHASE2","title":"Comparing Safety and Protective Efficacy of Vaccine Candidate PfSPZ-CVac and MVA ME-TRAP/ ChAd63 ME-TRAP in Adults","status":"NOT_YET_RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2025-06-01","conditions":"Malaria","enrollment":30},{"nctId":"NCT05604521","phase":"PHASE1","title":"A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Heterologous CHMI","status":"TERMINATED","sponsor":"Sanaria Inc.","startDate":"2022-12-06","conditions":"Malaria, Malaria,Falciparum","enrollment":31},{"nctId":"NCT05019729","phase":"PHASE1","title":"Trial to Evaluate L9LS in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-13","conditions":"Malaria","enrollment":32},{"nctId":"NCT04280692","phase":"PHASE1, PHASE2","title":"Controlled Human Malaria Infection Transmission Model - Phase A","status":"SUSPENDED","sponsor":"University of Oxford","startDate":"2022-08-22","conditions":"Malaria,Falciparum","enrollment":44},{"nctId":"NCT04250363","phase":"PHASE1","title":"Chemoprophylactic Activity of M5717 in PfSPZ Challenge Model","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2020-02-17","conditions":"Healthy","enrollment":39},{"nctId":"NCT04009096","phase":"PHASE2","title":"VAC071: A Study to Assess Efficacy of the ChAd63/MVA PvDBP Vaccines","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-07-18","conditions":"Malaria, Vivax","enrollment":16},{"nctId":"NCT03261401","phase":"PHASE1","title":"First-in-Human Trial of Single Ascending Dose, Multiple Ascending Dose and Malaria Challenge Model in Healthy Participants","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2017-09-15","conditions":"Healthy","enrollment":88},{"nctId":"NCT04327310","phase":"PHASE1","title":"Clinical Study of Meplazumab to Treat With Malaria","status":"WITHDRAWN","sponsor":"Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd","startDate":"2023-03","conditions":"Malaria (Plasmodium Falciparum)","enrollment":""},{"nctId":"NCT05095272","phase":"PHASE1","title":"Blood-Stage Plasmodium Vivax Cell Bank","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-02-15","conditions":"Malaria","enrollment":2},{"nctId":"NCT03589794","phase":"PHASE1","title":"rCSP/AP10-602 [GLA-LSQ] Vaccine Trial","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-12-21","conditions":"Plasmodium Falciparum Infection","enrollment":65},{"nctId":"NCT03377296","phase":"NA","title":"Study of Controlled Human Plasmodium Vivax Infection","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2018-03-03","conditions":"Malaria, Vivax","enrollment":2},{"nctId":"NCT03813108","phase":"NA","title":"Safety and Efficacy of NF135 CPS Immunization","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2019-04-01","conditions":"Malaria,Falciparum, Controlled Human Malaria Infection, Immunization; Infection","enrollment":43},{"nctId":"NCT04788862","phase":"NA","title":"A Study of Blood-stage Controlled Human Plasmodium Falciparum Malaria Infection in Tanzania","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2022-07-18","conditions":"Malaria, Plasmodium Falciparum","enrollment":12},{"nctId":"NCT04206332","phase":"PHASE1","title":"Trial to Evaluate CIS43LS in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-01-07","conditions":"Malaria","enrollment":71},{"nctId":"NCT04268420","phase":"PHASE1","title":"A Trial For The Study of Falciparum Malaria Protein 013 Administered Via Intramuscular Injection in Healthy Adults","status":"UNKNOWN","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2020-03-20","conditions":"Vaccine Reaction","enrollment":46},{"nctId":"NCT04966871","phase":"PHASE1","title":"Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults","status":"COMPLETED","sponsor":"Sanaria Inc.","startDate":"2021-09-27","conditions":"Malaria","enrollment":54},{"nctId":"NCT03952650","phase":"PHASE1, PHASE2","title":"Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falcipa...","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-05-23","conditions":"Malaria","enrollment":252},{"nctId":"NCT03138096","phase":"PHASE1, PHASE2","title":"Safety and Protective Efficacy of Pb(PfCS@UIS4)","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2017-05-29","conditions":"Malaria,Falciparum, Plasmodium Falciparum, Plasmodium Berghei","enrollment":24},{"nctId":"NCT02927145","phase":"PHASE1, PHASE2","title":"A Challenge Study to Assess the Safety, Immunogenicity and Efficacy of a Malaria Vaccine Candidate","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2016-10-17","conditions":"Malaria","enrollment":88},{"nctId":"NCT02562872","phase":"PHASE1","title":"DSM265 Prophylaxis of Plasmodium Falciparum Malaria","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2016-03","conditions":"Healthy","enrollment":24},{"nctId":"NCT03970993","phase":"PHASE1, PHASE2","title":"VAC 072-An Efficacy Study of R21/MM in Different Dose Schedules","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-06-17","conditions":"Malaria","enrollment":78},{"nctId":"NCT04310085","phase":"PHASE1","title":"Study in Blood Stage Malaria Infection After DVI of Cryopreserved P. Falciparum (NF54 Strain) Sporozoites","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2020-02-19","conditions":"Malaria,Falciparum, Parasitemia, Protozoan Infections","enrollment":16},{"nctId":"NCT01540474","phase":"PHASE1","title":"Trial of a Falciparum Malaria Protein (FMP012), E. Coli-expressed PfCelTOS, in Healthy Malaria-Naive Adults","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2012-02","conditions":"Malaria","enrollment":36},{"nctId":"NCT03014258","phase":"PHASE1","title":"A Systems Biology Approach to Malaria Immunity","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-06-07","conditions":"Plasmodium Falciparum Infection","enrollment":27},{"nctId":"NCT03083847","phase":"PHASE1","title":"Dose Escalation PfSPZ-CVac","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-06-05","conditions":"Malaria","enrollment":55},{"nctId":"NCT02627456","phase":"PHASE1","title":"Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites in Healthy African Adults in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-12-09","conditions":"Malaria","enrollment":409},{"nctId":"NCT04296279","phase":"PHASE1","title":"A Trial For The Study of Falciparum Malaria Protein 014 Administered Via Intramuscular Injection in Healthy Adults","status":"UNKNOWN","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2020-03-20","conditions":"Vaccine Reaction","enrollment":46},{"nctId":"NCT00761020","phase":"NA","title":"Merozoite Surface Protein 1 Antibody Response in Asymptomatic Human Malaria Infection","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2008-09","conditions":"Malaria","enrollment":31},{"nctId":"NCT03707041","phase":"PHASE1","title":"Safety, Tolerability and Chemoprotective Activity of P218 in PfSPZ Challenge Model","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2018-11-16","conditions":"Malaria","enrollment":32},{"nctId":"NCT03867331","phase":"PHASE1","title":"To Assess the Safety, Immunogenicity and Efficacy of VLPM01 in Healthy, Malaria-Naïve Volunteers","status":"COMPLETED","sponsor":"VLP Therapeutics","startDate":"2019-03-13","conditions":"Malaria,Falciparum","enrollment":36},{"nctId":"NCT03882528","phase":"PHASE1","title":"Evaluate the Infectivity Equivalence of Current and New Lots of Plasmodium Falciparum Strain NF54","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2019-03-04","conditions":"Malaria,Falciparum","enrollment":12},{"nctId":"NCT00367380","phase":"PHASE2","title":"Evaluation of Reproducibility of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers","status":"COMPLETED","sponsor":"Malaria Vaccine and Drug Development Center","startDate":"2006-12","conditions":"MALARIA, FEVER, Sweating Fever","enrollment":18},{"nctId":"NCT02450578","phase":"PHASE1","title":"DSM265 Chemoprophylaxis of Plasmodium Falciparum Malaria","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2015-10","conditions":"Plasmodium Falciparum, Malaria","enrollment":22},{"nctId":"NCT03162614","phase":"PHASE2","title":"Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-05-24","conditions":"Malaria","enrollment":154},{"nctId":"NCT03824236","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Immunogenicity and Safety in a Sporozoite Challenge Model of a Fractional Booster Dose of GSK Biologicals' Candidate Malaria Vaccine Administered to Previously Vaccinated Healthy Malaria-naïve Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-02-05","conditions":"Malaria","enrollment":61},{"nctId":"NCT03454048","phase":"NA","title":"Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2018-05-07","conditions":"Malaria,Falciparum, Gametocytes, Controlled Human Malaria Infection","enrollment":24},{"nctId":"NCT02431637","phase":"PHASE1","title":"Experimental Falciparum Transmission to Anopheles","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2015-04","conditions":"Malaria","enrollment":6},{"nctId":"NCT04203186","phase":"NA","title":"A Clinical Trial to Evaluate Plasmodium Falciparum 7G8 and NF54 Challenge Strains (PfSPZ) in a Head-to-head Comparative Study - (ECG-CHMI)","status":"WITHDRAWN","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2020-03","conditions":"Plasmodium Falciparum","enrollment":""},{"nctId":"NCT02867059","phase":"PHASE1","title":"SJ733 Induced Blood Stage Malaria Challenge Study","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2016-09-13","conditions":"Plasmodium Falciparum Malaria","enrollment":17},{"nctId":"NCT03278808","phase":"PHASE2","title":"Chloroquine (CQ) and Azithromycin (AZ) Combination for Malaria Prophylaxis","status":"WITHDRAWN","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2018-09-17","conditions":"Malaria","enrollment":""},{"nctId":"NCT03590340","phase":"PHASE1","title":"Regimen Optimization Trial of PfSPZ Vaccine in Equatorial Guinea","status":"COMPLETED","sponsor":"Sanaria Inc.","startDate":"2018-07-30","conditions":"Malaria","enrollment":104},{"nctId":"NCT02773979","phase":"PHASE1","title":"PfSPZ Challenge in Healthy Malaria-Naïve Adults in the United States","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-09-12","conditions":"Plasmodium Falciparum Infection","enrollment":28},{"nctId":"NCT02996695","phase":"PHASE1","title":"Safety and Efficacy of Sanaria's PfSPZ-CVac in Malian Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-04-06","conditions":"Plasmodium Falciparum Infection","enrollment":62},{"nctId":"NCT01024686","phase":"PHASE1, PHASE2","title":"Phase 1/2a Trial of Pf GAP p52-/p36- Sporozoite Malaria Vaccine","status":"TERMINATED","sponsor":"Seattle Children's Hospital","startDate":"2010-03","conditions":"Malaria","enrollment":6},{"nctId":"NCT03707353","phase":"PHASE1, PHASE2","title":"An Efficacy Study of IV Boosting With ChAd63/MVA ME-TRAP","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2018-10-30","conditions":"Malaria","enrollment":43},{"nctId":"NCT01994525","phase":"PHASE1","title":"Immunization Via Mosquito Bite With Radiation-attenuated Sporozoites","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2014-01-24","conditions":"Malaria","enrollment":54},{"nctId":"NCT04072302","phase":"PHASE1","title":"Safety and Causal Prophylactic Efficacy of KAF156 in a Controlled Human Malaria Challenge Model","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-09-15","conditions":"Malaria","enrollment":86},{"nctId":"NCT02543086","phase":"PHASE1","title":"Effectiveness of KAE609 in Reducing Asexual & Sexual Blood-stage P.Falciparum Infection & Infectivity to Mosquitos","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-07","conditions":"Plasmodium Falciparum Malaria","enrollment":8},{"nctId":"NCT02858817","phase":"PHASE1","title":"Safety and Protective Efficacy of IV Immunization With Cryopreserved PfSPZ Under A/P Chemoprophylaxis","status":"COMPLETED","sponsor":"University Hospital Tuebingen","startDate":"2016-11-28","conditions":"Malaria","enrollment":30},{"nctId":"NCT01857869","phase":"PHASE2","title":"Efficacy, Safety and Immunogenicity Study of GlaxoSmithKline(GSK) Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naïve Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-05-20","conditions":"Malaria","enrollment":64},{"nctId":"NCT01366534","phase":"PHASE2","title":"Safety, Immunogenicity and Efficacy Against of a Combined Malaria Vaccine in Healthy Malaria-naïve Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-08-10","conditions":"Malaria","enrollment":67},{"nctId":"NCT01157897","phase":"PHASE1, PHASE2","title":"Study of VMP001 and AS01B (Adjuvant Formulation) in Healthy Malaria-Naïve Adults","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2010-07","conditions":"Malaria, Plasmodium Vivax","enrollment":41},{"nctId":"NCT03906474","phase":"NA","title":"VAC063C: A Study to Assess Repeat Blood-stage P. Falciparum Infection","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2018-11-06","conditions":"Malaria","enrollment":11},{"nctId":"NCT03420053","phase":"PHASE1","title":"Study to Evaluate Safety, Immunogenicity and Efficacy of PfSPZ Vaccine in HIV Negative and HIV Positive Tanzanian Adults","status":"COMPLETED","sponsor":"Sanaria Inc.","startDate":"2018-02-07","conditions":"Malaria, Malaria,Falciparum","enrollment":21},{"nctId":"NCT02704533","phase":"PHASE1","title":"Sequential Optimization of Dose and Schedule of PfSPZ Vaccine","status":"COMPLETED","sponsor":"Sanaria Inc.","startDate":"2016-08-29","conditions":"Malaria","enrollment":45},{"nctId":"NCT02780154","phase":"PHASE1","title":"PfSPZ Challenge in Non-immune Adults in Baltimore, USA","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-08-25","conditions":"Plasmodium Falciparum Infection","enrollment":30},{"nctId":"NCT03496454","phase":"NA","title":"Susceptibility of Gambian Adults to PfSPZ-Challenge Infection in the Controlled Human Malaria Infection Model","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2018-03-29","conditions":"Malaria","enrollment":19},{"nctId":"NCT02601716","phase":"PHASE2","title":"PfSPZ Vaccine: Dose Optimization With Heterologous Challenge in Healthy Malaria-Naïve Adults","status":"COMPLETED","sponsor":"Sanaria Inc.","startDate":"2016-01","conditions":"Malaria","enrollment":92},{"nctId":"NCT02613520","phase":"PHASE1","title":"Safety and Immunogenicity in Age De-Escalation of PfSPZ Vaccine in Tanzanian Adults, Children, and Infants","status":"COMPLETED","sponsor":"Sanaria Inc.","startDate":"2015-12","conditions":"Malaria","enrollment":105},{"nctId":"NCT02859350","phase":"PHASE1","title":"Safety, Tolerability and Immunogenicity of PfSPZ Vaccine in an Age De-escalation Trial in Equatorial Guinea.","status":"COMPLETED","sponsor":"Sanaria Inc.","startDate":"2016-11","conditions":"Malaria","enrollment":135},{"nctId":"NCT00935623","phase":"PHASE1","title":"Clinical Trial for the Development of a Safe Malaria Challenge Model That Can be Reproduced in Humans","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2009-04-21","conditions":"Plasmodium Vivax Malaria","enrollment":12},{"nctId":"NCT01441167","phase":"PHASE1","title":"Experimental PfSPZ Vaccine in Adults Without Malaria","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-09-14","conditions":"Malaria, Prevention and Control, Acquired Immunity","enrollment":64},{"nctId":"NCT02905019","phase":"PHASE1, PHASE2","title":"A Safety and Efficacy Study of R21 +/- ChAd63/MVA ME-TRAP","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2016-08","conditions":"Malaria","enrollment":63},{"nctId":"NCT02836002","phase":"PHASE1, PHASE2","title":"Controlled Human Malaria Infection Model for Evaluation of Transmission-Blocking Interventions - Study 1","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2016-06","conditions":"Malaria","enrollment":29},{"nctId":"NCT03195387","phase":"PHASE1","title":"Chemoprotective Activity of MMV390048 in PfSPZ Challenge Model","status":"WITHDRAWN","sponsor":"Medicines for Malaria Venture","startDate":"2018-01","conditions":"Malaria,Falciparum","enrollment":""},{"nctId":"NCT02174978","phase":"PHASE1","title":"Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) to Evaluate the Safety and Efficacy of the Plasmodium Falciparum Vaccine Candidate FMP012 Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2014-08","conditions":"Malaria","enrollment":39},{"nctId":"NCT02511054","phase":"PHASE1","title":"Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Trial to Determine Safety and Protective Efficacy of Sanaria PfSPZ Challenge With Concurrent Pyrimethamine Treatment That Inhibits Development of Asexual B...","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-07-21","conditions":"Malaria","enrollment":57},{"nctId":"NCT02115516","phase":"PHASE1","title":"Safety and Protective Efficacy of Intravenous Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chemoprophylaxis","status":"COMPLETED","sponsor":"Sanaria Inc.","startDate":"2014-04","conditions":"Malaria, Plasmodium Falciparum Malaria","enrollment":67},{"nctId":"NCT01728701","phase":"PHASE1","title":"Controlled Human Malaria Infection (CHMI) After Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis","status":"COMPLETED","sponsor":"Sanaria Inc.","startDate":"2012-09","conditions":"Malaria, Plasmodium Falciparum","enrollment":30},{"nctId":"NCT02783833","phase":"PHASE1, PHASE2","title":"MMV390048 and Its Antimalarial Activity Against Plasmodium Falciparum in Healthy Adult Subjects, Part B","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2016-05","conditions":"Malaria","enrollment":15},{"nctId":"NCT02739763","phase":"PHASE1","title":"Controlled Human Malaria Infection in Semi-Immune Kenyan Adults. (CHMI-SIKA)","status":"UNKNOWN","sponsor":"University of Oxford","startDate":"2016-05","conditions":"Malaria","enrollment":200},{"nctId":"NCT02132299","phase":"PHASE1","title":"Dose Escalation, Randomized Controlled Trial to Evaluate the Safety, Immunogenicity and Efficacy of Intravenously Administered Attenuated Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in Tanzanian Adults","status":"COMPLETED","sponsor":"Sanaria Inc.","startDate":"2014-04","conditions":"Malaria, Plasmodium Falciparum Malaria","enrollment":67},{"nctId":"NCT01624961","phase":"PHASE1","title":"Controlled Human Malarial Infection by Intravenous Injection of Plasmodium Falciparum Sporozoites in Non-Immune Adults","status":"COMPLETED","sponsor":"Sanaria Inc.","startDate":"2012-06","conditions":"Malaria","enrollment":30},{"nctId":"NCT01771848","phase":"PHASE1","title":"Optimization of Controlled Human Malarial Infection by Injection of P. Falciparum Sporozoites in Non-Immune Adults","status":"COMPLETED","sponsor":"Sanaria Inc.","startDate":"2012-12","conditions":"Malaria","enrollment":36},{"nctId":"NCT02098590","phase":"NA","title":"Chemoprophylaxis and Plasmodium Falciparum NF54 Sporozoite Immunization Challenged by Heterologous Infection","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2014-10","conditions":"Malaria","enrollment":40},{"nctId":"NCT01972321","phase":"NA","title":"ICCM of Common Childhood Diseases: Mozambique and Uganda","status":"COMPLETED","sponsor":"Malaria Consortium","startDate":"2013-04","conditions":"Malaria, Pneumonia, Diarrhoea","enrollment":2289},{"nctId":"NCT02252640","phase":"PHASE1, PHASE2","title":"A Safety and Efficacy Study of Concomitant Administration of ChAd63/MVA ME-TRAP + RTS,S","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-01","conditions":"Plasmodium Falciparum Malaria","enrollment":48},{"nctId":"NCT00385047","phase":"PHASE1, PHASE2","title":"A Study to Determine Whether 2 Investigational Malaria Vaccines Are Safe, Protective Against Malaria in Adults","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2006-09","conditions":"Malaria","enrollment":41},{"nctId":"NCT00984763","phase":"PHASE1, PHASE2","title":"A Study to Assess Safety, Immunogenicity and Parasite Growth Inhibition of an Asexual Blood Stage Vaccine for P. Falciparum Malaria","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2010-01","conditions":"Malaria","enrollment":8},{"nctId":"NCT02237586","phase":"PHASE1","title":"Effect of Plasmodium Falciparum Exposure and Sickle Cell Trait on Infection Rates and Kinetics After IV Administration of PfSPZ Challenge","status":"COMPLETED","sponsor":"Sanaria Inc.","startDate":"2014-07","conditions":"Plasmodium Falciparum Malaria, Malaria","enrollment":25},{"nctId":"NCT01086917","phase":"PHASE1","title":"Experimental Human Malaria Infection by PfSPZ","status":"COMPLETED","sponsor":"Sanaria Inc.","startDate":"2010-08","conditions":"Malaria","enrollment":18},{"nctId":"NCT01623557","phase":"PHASE1, PHASE2","title":"A Challenge Study to Assess the Protective Efficacy of Two Malaria Vaccine Candidates","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2012-04","conditions":"Plasmodium Falciparum Malaria","enrollment":30},{"nctId":"NCT02044198","phase":"PHASE1, PHASE2","title":"A Phase I/IIa Study of the Safety, Immunogenicity and Efficacy of FMP2.1/AS01B, an Asexual Blood-Stage Vaccine for Plasmodium Falciparum Malaria","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2014-03","conditions":"Plasmodium Falciparum Malaria","enrollment":30},{"nctId":"NCT01783340","phase":"PHASE1, PHASE2","title":"Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine or Chloroquine/Azithromycin Prophylaxis","status":"WITHDRAWN","sponsor":"Radboud University Medical Center","startDate":"2013-04","conditions":"Malaria, Falciparum","enrollment":""},{"nctId":"NCT01883609","phase":"PHASE1, PHASE2","title":"A Safety and Efficacy Study of ChAd63/MVA METRAP + RTS,S","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2013-09","conditions":"Plasmodium Falciparum Malaria","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":109,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"Malaria Challenge","genericName":"Malaria Challenge","companyName":"U.S. Army Medical Research and Development Command","companyId":"u-s-army-medical-research-and-development-command","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":5,"visitCount":1,"trialStats":{"total":13,"withResults":6},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T10:12:10.881344+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":true,"trials":true,"score":2}}